FSA
BMRN icon

Franklin Street Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Franklin Street Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-20,715
Closed -$1.41M – 226
2014
Q1 		$1.41M Hold
20,715
– – 0.28% 84
2013
Q4 		$1.46M Buy
+20,715
New +$1.41M 0.29% 84

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Street Advisors's BMRN Position: Q2 2014 in Review

Franklin Street Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2014, closing a stake of 20,715 shares — an estimated $1.41M sold.

Franklin Street Advisors first reported a position in BMRN in Q4 2013 and held it in 2 quarters. The position peaked at $1.46M in Q4 2013. 321 funds tracked by Wall St. Rank hold BMRN as of Q2 2014.

  • Franklin Street Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Franklin Street Advisors sold 20,715 BioMarin Pharmaceuticals shares in Q2 2014, an estimated $1.41M.
  • Franklin Street Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Franklin Street Advisors's BioMarin Pharmaceuticals position peaked at $1.46M in Q4 2013.
  • 321 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2014.

Based on Franklin Street Advisors's 13F filing for Q2 2014, filed 8 Jul 2014.